【康方生物:依沃西联合辉瑞维恩妥尤单抗一线治疗UC国际II/III期研究启动】8月5日,康方生物宣布,其自研全球首创PD-1/VEGF双抗新药依沃西的海外合作伙伴Summit Therapeutics将开展依沃西联合维恩妥尤单抗对比帕博利珠单抗联合EV,一线治疗局部晚期或转移性尿路上皮癌的II/III期国际多中心注册性临床研究。目前,HARMONi-GU1的中国研究部分由康方生物负责推进,Summit负责开展HARMONi-GU1研究包括美国、欧洲等在内的海外研究部分。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.